Literature DB >> 36068277

Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis.

Stephanie Roessler1,2, Benjamin Goeppert3,4,5, Alphonse Charbel6,7, Luca Tavernar6,7, Thomas Albrecht6,7, Fritz Brinkmann6,7, Joanne Verheij8, Eva Roos8, Monika Nadja Vogel9, Bruno Köhler7,10, Christoph Springfeld7,10, Alexander Brobeil6,11, Peter Schirmacher6,7, Stephan Singer12, Arianeb Mehrabi7,13.   

Abstract

BACKGROUND: Intraductal papillary neoplasms (IPN) and biliary epithelial neoplasia (BilIN) are well-defined precursor lesions of biliary tract carcinoma (BTC). The aim of this study was to provide a comprehensive characterisation of the inflammatory microenvironment in BTC precursor lesions.
METHODS: Immunohistochemistry was employed to assess tumour-infiltrating immune cells in tissue samples from patients, for whom precursor lesions were identified alongside invasive BTC. The spatiotemporal evolution of the immune microenvironment during IPN-associated carcinogenesis was comprehensively analysed using triplet sample sets of non-neoplastic epithelium, precursor lesion and invasive BTC. Immune-cell dynamics during IPN- and BilIN-associated carcinogenesis were subsequently compared.
RESULTS: Stromal CD3+ (P = 0.002), CD4+ (P = 0.007) and CD8+ (P < 0.001) T cells, CD20+ B cells (P = 0.008), MUM1+ plasma cells (P = 0.012) and CD163+ M2-like macrophages (P = 0.008) significantly decreased in IPN compared to non-tumorous biliary epithelium. Upon transition from IPN to invasive BTC, stromal CD68+ (P = 0.001) and CD163+ (P < 0.001) macrophages significantly increased. In contrast, BilIN-driven carcinogenesis was characterised by significant reduction of intraepithelial CD8+ T-lymphocytic infiltration from non-tumorous epithelium via BilIN (P = 0.008) to BTC (P = 0.004).
CONCLUSION: IPN and BilIN are immunologically distinct entities that undergo different immune-cell variations during biliary carcinogenesis. Intraepithelial CD8+ T-lymphocytic infiltration of biliary tissue decreased already at the IPN-precursor stage, whereas BilIN-associated carcinogenesis showed a slowly progressing reduction towards invasive carcinoma.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36068277     DOI: 10.1038/s41416-022-01933-0

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  49 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Anatomical, histomorphological and molecular classification of cholangiocarcinoma.

Authors:  Timothy Kendall; Joanne Verheij; Eugenio Gaudio; Matthias Evert; Maria Guido; Benjamin Goeppert; Guido Carpino
Journal:  Liver Int       Date:  2019-05       Impact factor: 5.828

3.  The tumor microenvironment at a glance.

Authors:  Frances R Balkwill; Melania Capasso; Thorsten Hagemann
Journal:  J Cell Sci       Date:  2012-12-01       Impact factor: 5.285

4.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.

Authors:  Oliver Clements; Joseph Eliahoo; Jin Un Kim; Simon D Taylor-Robinson; Shahid A Khan
Journal:  J Hepatol       Date:  2019-09-16       Impact factor: 25.083

Review 5.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 6.  Balancing the innate immune system in tumor development.

Authors:  Catharina Hagerling; Amy-Jo Casbon; Zena Werb
Journal:  Trends Cell Biol       Date:  2014-11-28       Impact factor: 20.808

Review 7.  Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?

Authors:  Chiara Braconi; Stephanie Roessler; Beata Kruk; Frank Lammert; Marcin Krawczyk; Jesper B Andersen
Journal:  Liver Int       Date:  2019-03-24       Impact factor: 5.828

Review 8.  Current and emerging therapies for advanced biliary tract cancers.

Authors:  Audrey E Kam; Ashiq Masood; Rachna T Shroff
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-11

9.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Authors:  Ghassan K Abou-Alfa; Vaibhav Sahai; Antoine Hollebecque; Gina Vaccaro; Davide Melisi; Raed Al-Rajabi; Andrew S Paulson; Mitesh J Borad; David Gallinson; Adrian G Murphy; Do-Youn Oh; Efrat Dotan; Daniel V Catenacci; Eric Van Cutsem; Tao Ji; Christine F Lihou; Huiling Zhen; Luis Féliz; Arndt Vogel
Journal:  Lancet Oncol       Date:  2020-03-20       Impact factor: 41.316

Review 10.  Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.

Authors:  Aarti Sharma; Kiran Lata Sharma; Annapurna Gupta; Alka Yadav; Ashok Kumar
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.